Rigel Pharmaceuticals reported $110.44M in Current Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agenus AGEN:US USD 251.43M 37.5M
Amgen AMGN:US USD 22.19B 1.88B
Anika Therapeutics ANIK:US USD 167.76M 95K
Arrowhead Research ARWR:US USD 405.3M 27.09M
AstraZeneca AZN:LN USD 20.22B 693M
Astrazeneca AZN:US USD 20.22B 693M
Biomarin Pharmaceutical BMRN:US USD 2.68B 165.1M
Celldex Therapeutics CLDX:US USD 334.6M 33.38M
Daiichi Sankyo 4568:JP JPY 1.44T 19.68B
Halozyme Therapeutics HALO:US USD 653.2M 111.26M
Heron Therapeutics HRTX:US USD 223.8M 29.6M
Immunogen IMGN:US USD 330.42M 63.51M
Intrexon XON:US USD 162.81M 1.81M
Karyopharm Therapeutics KPTI:US USD 222.68M 19.77M
Ligand Pharmaceuticals LGND:US USD 220.43M 23.35M
Macrogenics MGNX:US USD 147.81M 19.82M
Neurocrine Biosciences NBIX:US USD 1.21B 186.2M
Regeneron Pharmaceuticals REGN:US USD 22.06B 6.64B
Rigel Pharmaceuticals RIGL:US USD 110.44M 10.08M
Sangamo Biosciences SGMO:US USD 336.62M 6.5M
Ultragenyx Pharmaceutical RARE:US USD 1.01B 334.13M
Veracyte VCYT:US USD 238.52M 3.47M